SS-31 (Elamipretide) Research Overview
SS-31 research is centred on mitochondrial membranes, especially cardiolipin-rich inner-membrane environments. The peptide is often described as a mitochondria-targeted antioxidant, but that shorthand can hide the more specific membrane, lipid and protein-interaction questions investigated in the literature.
Cardiolipin is central to the SS-31 research model
Cardiolipin is an anionic phospholipid enriched in the inner mitochondrial membrane and involved in organising membrane proteins and cristae structure. Birk and colleagues used a fluorescent SS-31 analogue and reported high-affinity interaction with cardiolipin. In a renal-ischaemia model, SS-31/cardiolipin interaction was associated with reduced cytochrome-c peroxidase activity, preservation of mitochondrial cristae and faster ATP recovery after reperfusion. PubMed.
The useful mechanistic point is not simply “antioxidant activity”. The experiment connects a peptide–lipid interaction with changes in membrane/protein behaviour under a specific injury model.
Membrane physics matters
Biophysical work has shown that SS-31 partitions into membrane interfacial regions in a surface-charge-dependent manner and can alter lipid packing without simply disrupting the bilayer. PubMed.
This supports a membrane-organisation interpretation: charge distribution and lipid composition can influence where the peptide associates and how the local membrane environment changes. A cell-free membrane result is not the same evidence level as an animal or human outcome.
Protein-interaction mapping adds another layer
Chemical cross-linking and mass-spectrometry research identified mitochondrial proteins interacting with SS-31, including proteins associated with oxidative phosphorylation and 2-oxoglutarate metabolism. Several mapped interactions were close to known cardiolipin-interaction regions. PubMed.
Interaction mapping identifies candidate molecular relationships. It does not establish one universal direct target responsible for every reported SS-31 effect.
How to read SS-31 evidence
| Evidence type | What it can establish | What it cannot establish alone |
|---|---|---|
| Cardiolipin binding | Association with a relevant mitochondrial phospholipid | A complete mechanism for all cellular effects |
| Model membranes | Effects on lipid packing/interfacial behaviour | Whole-organism efficacy |
| Cross-linking/proteomics | Candidate protein interactions and proximity | A single necessary direct target |
| Injury models | Model-specific mitochondrial/tissue endpoints | Clinical benefit or product equivalence |
SS-31 and regulated elamipretide products
The same scientific name can appear in basic research, investigational studies and regulated medicinal contexts. Those finished products can differ in formulation, manufacturing controls, specifications and intended use. A medicinal or investigational formulation does not authenticate a separate Core Research RUO vial.
Analytical identity and batch documentation
Exact sequence, non-standard residues, terminal form, salt/counter-ion, mass assignment, chromatographic result and lot identity should be confirmed from the applicable product record. Use Batch Documentation and the mass-spectrometry guide to separate reference identity from lot evidence.
Core Research catalogue context
The SS-31 10mg product page describes the supplied catalogue presentation. MOTS-c, NAD+ and other materials in the metabolic category address different research questions and are not substitutes for SS-31.
Research-use boundary
This guide does not provide human dosing, administration or treatment guidance. Core Research SS-31 material is supplied for laboratory research use only, not for human or veterinary use.
Selected references
- Birk AV, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. PMID 23813215.
- Biophysical analysis of SS-31 interactions with mitochondrial-membrane lipid systems. PMID 32273339.
- SS-31 mitochondrial protein-interaction mapping by chemical cross-linking/mass spectrometry. PMID 32554501.